The quest for an effective Alzheimer’s treatment continues as recent trials of solanezumab, a monoclonal antibody targeting monomeric amyloid, yield disappointing results in slowing cognitive decline. Original Article:
State of Health Podcast:
Join this channel to get access to perks: